Celsion Corporation (CLSN)

[sdtrond]

Rawnoc,

You asserted that placebo PFS in HEAT will be "way under" 12 months. You provide nothing to back this up except saying mgmt has only spoken of local progression wrt 12 months.

I provided a section of the recent cc where MT says 12 months when talking about the expected placebo PFS in the HEAT trial. NO he did not specify "the overall placebo", but he's talking about the overall trial and he did NOT say "only local" in that section. Since he did NOT modify the wording in any way, I'm going to continue to believe mgmt is talking about overall stats, including local and distant, ex-hep mets, and death.

When challenged all you do is change the argument to what percentage recur. I'm not arguing that.

If you want some company provided stats on that, by the way, look at page 5 from the 'Presentation at the 2012 Annual Congress of the Cardiovascular and Interventional Radiological Society of Europe by Professor Ronnie T.P. Poon "Thermosensitive Liposome in Combination with Thermal Ablation"', available at http://investor.celsion.com/events.cfm.

This shows seven studies of RFA, with local recurrence averaging around 11% after an average of about 21 months follow up. Nothing here shows actual time to recurrence, but if only 7-15% recur after 21 months follow up, I hardly see where you can argue 50% in HEAT will recur in less than 12 months.

So what IS your prediction? It'd be nice to see a number rather than your "Way Under 12!!!!!" bravado.